Article
Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.
Leukemia - 1 Jan 2019
Tasian Sarah K, Casas Jessica A, Posocco David, Gandre-Babbe Shilpa, Gagne Alyssa L, Liang Ge, Loh Mignon L, Weiss Mitchell J, French Deborah L, Chou Stella T
Abstract excerpt
Juvenile myelomonocytic leukemia (JMML) is an uncommon myeloproliferative neoplasm driven by Ras pathway mutations and hyperactive Ras/MAPK signaling. Outcomes for many children with JMML remain dismal with current standard-of-care cytoreductive chemotherapy and hematopoietic stem cell transplantation. We used patient-derived induced pluripotent stem cells (iPSCs) to characterize the signaling profiles and...
Topics
- Child
- Humans
- Induced Pluripotent Stem Cells
- Leukemia, Myelomonocytic, Juvenile
- Mutation
- Neoplastic Stem Cells
- Protein Kinase Inhibitors
- Protein Kinases
- Signal Transduction
- Tumor Cells, Cultured